Hemab Secures $157m in Funding for Bleeding Disorder Treatments
Hemab Therapeutics has successfully completed an oversubscribed Series C funding round,raises $157m to further develop therapies for bleeding disorders.
Following the completion of a Phase II trial of sutacimig, Hemab is preparing to progress to a registration trial in 2026.
- The investment round was led by Sofinnova Partners.
- A global asset management company also contributed to the round.
- New investors, including a sovereign wealth fund and Avoro Capital Advisors, joined the round.
- Existing stakeholders, such as Access Biotechnology and Novo Holdings, continued their support.
As a result of this funding, Sofinnova partner Joe Anderson will join the Hemab board.
No direct quotes available in this text.
Author's summary: Hemab raises $157m for bleeding disorder treatments development.
More News
- Where to Kill a Buck This Weekend: Target These Key Food Sources and Scrapes
- The Angel Ball Honors Tina Knowles
- Travel-Ready Base Layers That Simplify Packing
- Nicole Kidman thriving while Keith Urban struggles after split
- Lifeway search committee now accepting nominations - The Christian Index
- Man Utd plot shock signing of Real Madrid star; TWO hurdles must be cleared for spectacular deal
- Eintracht Frankfurt Borussia Dortmund 28 10 2025 Live Score and Match Summary
- Nick Offerman and Lee K. Buchanan Close Out Arts and Humanities Day with a Love Letter to Carpentry, Family, and the Pursuit of Hands-On Work in the Digital Age
- Sequoias Versus Redwoods: What's the Difference and How to Compare the National Parks in California
- Looking back: Local ghost legends